Skip to main content

Advertisement

Table 3 Effect of VigRX Plus on the IIEF domains

From: Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study

IIEF Domains VigRX Plus Placebo
  Baseline EoT Change 95%CI Baseline EoT Change 95%CI
EF,Q1-5,15 16.08 (2.87) 25.08 (4.56)* 9 (4.95) 7.40,10.60 15.86 (3.24) 16.47 (4.25) 0.61(2.43) −0.21,1.43
Q1 3.38 (0.67) 4.64 (0.67) 1.26 (0.88) 0.98,1.54 3.33 (0.53) 3.38 (0.77) 0.06 (0.58) −0.14,0.25
Q2 2.71(0.65) 4.17 (0.82) 1.46 (0.94) 1.16,1.76 2.66 (0.63) 2.80 (0.75) 0.14 (0.42) −0.0,0.28
Q3 2.69 (0.57) 4.12 (0.80) 1.43 (0.85) 1.15,1.70 2.63 (0.59) 2.75 (0.69) 0.11(0.46) −0.05,0.26
Q4 2.56 (0.50) 4.02 (0.81) 1.46 (0.91) 1.16, 1.76 2.44 (0.56) 2.66 (0.68) 0.22 (0.48) 0.06, 0.38
Q5 2.23 (0.78) 3.94 (0.89) 1.71 (1.02) 1.38, 2.04 2.27 (0.85) 2.33 (0.89) 0.06 (0.47) −0.10, 0.21
Q15 2.48 (0.56) 4.15 (0.87) 1.66 (1.03) 1.33, 1.99 2.5 (0.56) 2.52 (0.84) 0.03 (0.56) −0.16, 0.21
IS, Q6-8 7.28 (1.70) 11.58 (2.46)* 4.3 (2.47) 3.50,5.10 7.13 (1.76) 7.72(1.98) 0.58 (1.44) 0.09,1.07
OF, Q9-10 7.84 (0.93)9( 9.23 (1.13)* 1.38 (1.24) 0.98,1.78 7.77 (1.20) 7.77 (1.53) 0.0 (0.92) −0.31,0.31
SD,Q11-12 6.35 (1.11) 9.05 (1.36)* 2.69 (1.73) 2.13,3.25 6.47 (1.28) 6.41 (1.5) −0.05 (1.62) −0.60,0.50
OS, Q13-14 5.46 (1.10) 8.17 (1.73)* 2.71 (1.86) 2.10,3.31 5.61 (0.96) 5.47 (1.50) −0.14 (0.90) −0.45,0.16
Total IIEF,Q1-15 42.56 (5.09) 63.13 (10.06)* 20.10 (11.08) 16.51,23.69 42.54 (5.10) 43.86 (8.45) 1.0 (5.73) −0.93,2.93
  1. IIEF scores are expressed as Mean (SD), *P < 0.001 is statistically significant for change from baseline as compared to placebo.CI, confidence intervals; EF, erectile function; EoT, end of treatment; IS, intercourse satisfaction; OF, orgasmic function; OS, overall satisfaction; SD, sexual desire.